75%Confidence
0Views
SEC EDGARSource
2026-04-07Date
Summary
Opus Genetics, Inc. filed an 8-K, likely announcing significant events such as clinical updates, funding rounds, or leadership appointments in the gene therapy field. This could drive investor interest or concern depending on the news content.
Actionable: Assess the 8-K for details on Opus Genetics' pipeline advancements or corporate changes that may affect its stock trajectory.
AI Confidence: 75%
Data Points
companyOpus Genetics, Inc. (IRD) (CIK 0001228627)
form8-K
date2026-04-07
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now